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E-mail: pilar.blancafort@uwa.edu.auPrecise clustered regularly interspaced short palindromic re-
peats (CRISPR)-mediated genetic and epigenetic manipulation
of the immune response has become a promising immunother-
apeutic approach toward combating tumorigenesis and tumor
progression. CRISPR-based immunologic reprograming in
cancer therapy comprises the locus-specific enhancement of
host immunity, the improvement of tumor immunogenicity,
and the suppression of tumor immunoevasion. To date, the
ex vivo re-engineering of immune cells directed to inhibit the
expression of immune checkpoints or to express synthetic im-
mune receptors (chimeric antigen receptor therapy) has shown
success in some settings, such as in the treatment of melanoma,
lymphoma, liver, and lung cancer. However, advancements in
nuclease-deactivated CRISPR-associated nuclease-9 (dCas9)-
mediated transcriptional activation or repression and Cas13-
directed gene suppression present novel avenues for the
development of tumor immunotherapies. In this review, the
basis for development, mechanism of action, and outcomes
from recently published Cas9-based clinical trial (genetic edit-
ing) and dCas9/Cas13-based pre-clinical (epigenetic editing)
data are discussed. Lastly, we review cancer immunotherapy-
specific considerations and barriers surrounding use of these
approaches in the clinic.
The human immune response consists of a complex and diverse array
of molecular and cellular processes to differentiate between self and
non-self, which allows it to defend and protect the host from path-
ogen infection, cellular damage, or neoplastic transformation. In
the context of cancer, the constant selective pressure exerted by the
host immune response often results in the selection of tumor variants
capable of immune evasion that enable tumor cells to survive.
Broadly, these tumor evasion mechanisms can involve (1) the accu-
mulation of suppressive cells, such as CD4+CD25+FoxP3+ regulatory
T cells (Tregs), in the cellular microenvironment;1,2 (2) down-modu-
lation of the antigen processing and presentation pathways within the
cancer cell;3–5 (3) shedding of stress, damage, or transformation
markers at the cancer cell surface, including the six UL16 binding592 Molecular Therapy: Methods & Clinical Development Vol. 21 June 2
This is an open access article under the CC BY-NC-ND license (httpproteins (ULBP1–ULBP6) and major histocompatibility complex
(MHC) class I polypeptide-related sequence A (MICA) and B
(MICB);6–8 (4) secretion of immunosuppressive cytokines, particu-
larly transforming growth factor b (TGF-b), vascular endothelial
growth factor (VEGF), and interleukin-10 (IL-10), into the surround-
ing microenvironment;9–12 and (5) upregulation of immune check-
point ligands, especially those pertaining to the programmed cell
death-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4)
pathways.13–17 Although the last few decades have brought an
improved understanding of the underlying molecular mechanisms
of these immune evasion strategies, the development of safe and
broadly effective immunotherapies that overcome these barriers
and are applicable to multiple cancer types remains a formidable
task. Accordingly, considerable research focus has been directed to-
ward harnessing the high specificity of clustered regularly interspaced
short palindromic repeats (CRISPR)-mediated genetic and epigenetic
editing as emerging precision therapeutics to counter the aforemen-
tioned immune evasion mechanisms and improve anti-tumor
immunity.
Numerous reviews to date have explored CRISPR-mediated genetic
and epigenetic editing, yet comprehensive overviews of clinical and
pre-clinical CRISPR technologies in cancer immunotherapy, particu-
larly in the emerging epigenetic editing space, remain scarce. In this
review, a brief outline of the mechanisms underlying the CRISPR-
Cas9 (CRISPR-associated protein 9), dCas9 (nuclease deactivated
Cas9) and Cas13 processes is presented, which encompasses the
most advanced and clinically relevant DNA and RNA-targeting
CRISPR systems developed thus far.18 This is then followed by an up-
date on clinical Cas9-based and pre-clinical dCas9- and Cas13-medi-
ated anti-tumor immunotherapies.021 ª 2021 The Author(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).








FnCas9 1,629 Francisella novicida NGG 22









NmCas9 1,109 Neisseria meningitides NNNNGATT 23,29,30
SaCas9 1,053 Staphylococcus aureus NNGRRN 31,32
CjCas9 984 Campylobacter jejuni NNNVRYM 33,34
aN = A/C/T/G; W = A/T; R = A/G; V = A/G/C; Y = T/C; M = A/C.
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ReviewCRISPR-CAS-BASED SYSTEMS ALLOW FOR
TARGETED GENETIC AND EPIGENETIC EDITING
The CRISPR-Cas9 system
Originally identified as a key defensive mechanism against invading
viruses and plasmids in prokaryotic genomes,19,20 CRISPR-Cas sys-
tems have since been adapted for RNA-programmable genome edit-
ing.21 Themost common and best studied of the CRISPR-Cas systems
are those that involve the large, multi-domain endonuclease,
CRISPR-associated protein 9 (Cas9). The DNA cleavage by Cas9 re-
quires a single-stranded short guide RNA (sgRNA), consisting of a
programmable target-specific 20-nt CRISPR RNA (crRNA) base
paired to a small non-coding trans-activating crRNA (tracrRNA).
Additionally, Cas9 requires a conserved protospacer-adjacent motif
(PAM) sequence for activity that maps upstream and adjacent to
the crRNA-binding region. The PAM sequence varies depending
on the organism of origin and affects the frequency and specificity
of the editing process (Table 1). Upon sequence-specific binding be-
tween the crRNA and target DNA, the Cas9 protein is recruited to the
PAM sequence via its PAM-interacting domain. After binding, the
separation of the target DNA is initiated at the PAM-adjacent nucle-
ation site and double-stranded breaks (DSBs) are produced. The
DSBs can be repaired by either homology-directed repair (HDR) or
non-homologous end-joining (NHEJ) (Figure 1A).21,26 The efficiency
of genome editing in this way varies greatly and is dependent on
several factors, including the nature of the target and delivery method
used. Notably, Mussolino et al.35 reviewed the editing frequencies
achieved in the case of the hematopoietic system and found that
ex vivo editing is often 10%–30% efficient, whereas in vivo editing
varies between 1% and 16%. However, with an optimized delivery sys-
tem specific for the target cells, the Cas9 editing efficiency can in-
crease up to 80%.36,37
The CRISPR-dCas9 system
Beyond the success of the CRISPR-Cas9 system, the creation of the
nuclease-deactivated Cas9 (dCas9) variant38 has widened the scope
of CRISPR technologies into the field of epigenome engineering. The
CRISPR-dCas9 system differs from the wild-type by two mutationsMolecul(D10A and H840A), which inactivate Cas9’s cleavage capacity, while
maintaining its RNA-guided DNA-binding specificity.38 As initially
shown with engineered zinc finger proteins,39–46 dCas9 can be fused
with various effector domains to mediate precise and programmable
transcriptional activation or repression, editing of epigenetic marks,
and fluorescent tagging of endogenous genes, all without directly edit-
ing the genome (Figure 1B).47–52
Locus-specific transcriptional manipulation in a guide-dependent
manner was first achieved by fusing the VP64 (four copies of VP16,
a herpes simplex virus transcription factor) recruiter of transcrip-
tional activators,53–55 as well as Krüppel-associated box (KRAB)
recruiter of transcriptional repressors,38,53 to dCas9. Since then,
more complex arrays of mechanistically distinct effector domains
have been described, which greatly improve the capability of dCas9
to induce transcriptional changes. This includes the VPR (tandem
fusion of VP64, p65, and Rta domains56 to generate the hybrid tripar-
tite activator) in the case of gene activation, and the tandem fusion of
KRAB with the TRD domain ofMeCP2 to produce the dCas9-KRAB-
MeCP2 repressor.57
As the arrays of effectors directly fused to dCas9 increase the size of
the resulting protein, which in turn impact the expression of dCas9
and the intracellular delivery, alternative assembly methods have
been developed. Notably, aptameric motifs engineered in combina-
tion with the gRNA scaffold (such as two copies of an RNA hairpin
from the MS2 bacteriophage) were first described in the context of
gene activation with the synergistic activation mediator (SAM) sys-
tem.58 This approach has been exploited to combine multiple acti-
vator domains derived from epigenetic enzymes, such as the catalytic
domain of DNA demethylases (e.g., TET159,60) or histone acetyltrans-
ferases (e.g., p30061), to generate high levels of gene activation. Alter-
natively, repetitive peptide arrays that amplify and recruit specific
designer antibody-fusion proteins can be fused to dCas9, as shown
in the supernova tagging (SunTag)62 system. The dCas9-SunTag is
based on single-chain variable fragment antibodies and the corre-
sponding epitope, which offers major advantages, including high af-
finity and recognition of short peptide sequences. This system has
previously been adapted to recruit DNA methyltransferases,
including DNMT3A63 and DNMT3L,64 in order to induce locus-spe-
cific repression via DNA methylation, with minimal off-target bind-
ing.65 Importantly, these next-generation dCas9 systems (SAM and
SunTag) provide highly specific, effective, and tunable tools for tar-
geted epigenetic manipulation. Lastly, the further development of
these technologies to enable simultaneous expression of multiple
gRNAs (multiplexed transcriptional manipulation of distinct
genes)66,67 continues to widen the scope and translatability of
dCas9-based epigenetic editing.
In the arena of oncology, these dCas-based tools have demonstrated
significant activation of tumor suppressor genes, such as PTEN (in
breast cancer and melanoma),48 MASPIN (in breast and lung
cancers),47,49 REPRIMO (in breast and gastric cancers),47 SARI
(in colon cancer),68 and DKK3 (in prostate cancer).69 Similarly,ar Therapy: Methods & Clinical Development Vol. 21 June 2021 593
Figure 1. Mechanisms underlying CRISPR-Cas9, dCas9, and Cas13 processes
(A) A 20-nt programmable CRISPR RNA (crRNA) directs the Cas9 complex to the target DNA. Upon recognition of the protospacer-adjacent motif (PAM) sequence at the
target location, the DNA strand is separated and Watson-Crick base pairing between the genomic DNA and crRNA is achieved. The HNH domain cleaves the target DNA
strand complementary to the crRNA sequence, whereas the RuvC domain cleaves the non-complementary strand. If no donor-corrected template is available, non-ho-
mologous end joining (NHEJ) occurs whereby random insertions and/or deletions are incorporated, rendering the gene non-functional or disrupted. Alternatively, if a template
is available, homology-directed repair (HDR) is initiated, where the provided template is inserted into the cut genomic DNA, thereby allowing for gene correction or addition. (B)
Mutations (D10A, H840A) in both cleavage domains of Cas9 generates a nuclease-deactivated protein (dCas9). Despite no cleavage activity, dCas9 preserves its high
binding specificity and searching capability. Therefore, fusion of dCas9 to specific domains expands its functionality to transcriptional repression (red) or activation (blue),
fluorescent tagging (green), and/or epigenetic writing or erasing (purple), such as methylation (+Me), demethylation (Me), acetylation, and chromatin reading or remodeling.
(C) A 28- to 30-nt programmable crRNA directs the Cas13 complex to the target single-stranded RNA (ssRNA) transcript. Watson-Crick base pairing between the target
ssRNA and crRNA initiates non-specific splicing of the target transcript, as well as any nearby transcripts, irrespective of complementarity to the crRNA. This collateral RNase
activity is attributed to Cas13’s promiscuous dual HEPN domains. (D) An arsenal of Cas13-crRNA complexes can be programmed to target sites across any ssRNA
transcript. Cleavage of RNA in this way allows for inhibition of post-transcriptional gene expression.
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ReviewdCas9-mediated oncogene suppression has been achieved success-
fully in colon cancer (BRAF,70 HER2,71 and MYC72), pancreatic can-
cer (KRAS),70 and liver cancer (GRN).73 In addition, several works
outline that epigenome editing can be highly efficient, having
achieved nearly complete gene repression38 or robust (several fold)
gene activation,56 with minimal off-target effects, which mainly
depend on the nature of effector domains used. For the most studied594 Molecular Therapy: Methods & Clinical Development Vol. 21 June 2domains, such as VP64 and KRAB, off targets have been shown to be
either zero or have negligible effects on non-cognate gene transcrip-
tion.74 Finally, whereas Cas9 genome engineering unavoidably results
in permanent changes, epigenetic approaches are reversible, circum-
venting the risk of inducing sequence changes in the target DNA,71,75
a key factor in the targeting of tumors harboring high degrees of ge-
netic instability. Moreover, the durability of the epigenetic and021
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Reviewtranscriptional changes induced by dCas9 editing can vary depending
on the specific combination of effectors and may be dependent on the
targeted loci. Thus, current research in the field of epigenome engi-
neering faces the challenge to adapt the technology for the manipula-
tion of different loci in diverse cell types with differing chromatin
microenvironments.76
The CRISPR-Cas13 system
The reduced RNA-cleavage efficiency and the likelihood for off-
target effects on host DNA have meant that RNA-targeting ortho-
logs of Cas9 are unlikely to be useful in targeting RNA transcripts
directly, such as non-coding RNA (ncRNA), messenger RNA
(mRNA), or viral RNA genomes.77,78 Moreover, existing RNA inter-
ference (RNAi) technologies also exhibit substantial off-target
effects.79 As such, increasing focus is being directed toward the
development of novel CRISPR-based technologies utilizing RNA-
specific Cas proteins. To date, the most successful of these technol-
ogies are those exploiting Cas13, of which four subtypes have been
identified thus far: Cas13a (formerly known as C2c2), Cas13b,
Cas13c, and Cas13d.80 In prokaryotes, Cas13 functions as an
RNA-guided RNA endonuclease and operates as a defensive mech-
anism specific for viral RNAs.81 Unlike Cas9, the Cas13 effector
family contains two higher eukaryotes and prokaryotes nucleotide-
binding (HEPN) domains as its catalytic effectors, which confer
RNase activity (Figure 1C). In addition, the Cas13 protein can
form a complex with multiple crRNAs to cleave at multiple locations
along an RNA transcript with high specificity and offers an alterna-
tive gene knockdown method to RNAi technologies (Figure 1D).82,83
Beyond Cas13’s cleavage capability, Zhang and colleagues84–86 have
pioneered the potential of catalytically inactive Cas13 (dCas13) in
several applications. In particular, dCas13 has been fused with fluo-
rescent tags to precisely label target RNA molecules and assess RNA-
specific intracellular localization. Similarly, the fusion of dCas13
with deaminase domains from adenosine deaminases specific for
RNA (ADARs) has been shown to mediate precise RNA editing to
alter full-length transcripts containing pathogenic mutations.
Individually and in combination, Cas9, dCas9, and Cas13 have shown
great promise as therapeutic options for multiple diseases, such as
cancer,70,87,88 viral infection,82,89,90 non-viral infection,91,92 and auto-
immunity.93,94 In oncology, the ability of CRISPR-Cas to efficiently
and specifically knock out (Cas9) or repress (dCas9 and Cas13)
pro-tumorigenic genes or transcripts opens new strategies for tumor
suppression.95–97Moreover, the same system can be used to introduce
(Cas9) or activate (dCas9) important immune-related genes to
directly improve the host immune response.95,96 Consequently, the
capacity of CRISPR-based systems to work individually as therapeu-
tics and in combination with current immunotherapy strategies is
developing into an emerging area of interest.
THE CRISPR-CAS9 SYSTEM DEMONSTRATES
SAFETY IN ADOPTIVE T CELL IMMUNOTHERAPY
As of March 1, 2020, there have been 21 registered trials utilizing
CRISPR-Cas systems aiming to genetically alter human T cells—aMoleculkey adaptive immune cell type that responds specifically to antigens
and is critical in host immunity (Table 2). These trials constitute
approximately 48% (21/43) of all trials using CRISPR on the
ClinicalTrials.gov registry. Recently, results from the first three
CRISPR-Cas9 clinical trials were published by Jing et al.98 (Clinical-
Trials.gov: NCT03081715), Lu et al.99 (ClinicalTrials.gov:
NCT02793856), and Stadtmauer et al.100 (ClinicalTrials.gov:
NCT03399448). Outcomes from these trials are discussed below.
PD-1 knockout T cells
Many tumors, including esophageal squamous cell carcinoma
(ESCC) and non-small cell lung cancer (NSCLC), express immune
checkpoint PD-1 ligands (PD-L1s) that bind to PD-1 receptors on
host T cells to inhibit their proliferation and cytokine production,
thereby enabling immunoevasion (Figure 2).101–103 To date, anti-
PD-1 and anti-PD-L1 monoclonal antibodies have shown success
in many cancers, including melanoma,104 Hodgkin’s lymphoma,105
liver cancer,106 and lung cancer.107 However, given the potential of
PD-1/PD-L1 inhibitor therapy to result in severe toxicity,108,109 ge-
netic disruption of PD-1 expression on host T cells is seen as an alter-
native and potentially safer immunotherapeutic avenue. Jing et al.98
and Lu et al.99 independently investigated the safety of PD-1
knockout T cell reinfusion in 17 patients with advanced ESCC and
12 patients with metastatic NSCLC, respectively. In both trials,
adoptive cell transfer (ACT) was used, whereby peripheral blood
mononuclear cells (PBMCs) were collected, followed by ex vivo
CRISPR-Cas9-mediated PD-1 (PDCD1 gene) knockout. The edited
PBMCs were then selected, expanded, and reinfused back into each
patient. In both studies, the regimen was well tolerated, with no
serious (grade 3/4) treatment-related adverse events observed. No
complete or partial responses were witnessed in either trial; however,
approximately 35% (6/17) of ESCC patients and 18% (2/11; early
withdrawal by one patient due to bacterial infection) of NSCLC pa-
tients exhibited stable disease. Results by Lu et al.99 demonstrated
that co-transfection of Cas9 and sgRNA plasmid DNA (pDNA) via
electroporation resulted in a low median editing efficiency of 5.81%
(range, 0.42%–24.85%) in the 12 enrolled patients. In the edited
PBMC pool, a median of 99.1% of cells were CD3 positive (range,
95.9%–99.6%), with CD3+CD8+ T cells accounting for 73.5% (range,
38.5%–93.0%). Whole-genome sequencing at 100-fold coverage tar-
geted toward 2,086 sites determined by Cas-OFFinder110 detected
no true off-target events, which constitute arguably the greatest cause
for concern in CRISPR-Cas9 clinical applications. Ultimately, both
trials appear to confirm that only minor (grade 1/2) adverse effects,
including fatigue, fever, joint pain, and skin rash, were attributed to
the treatment, suggesting that CRISPR-Cas9-mediated ACT may be
safe for clinical use. Moreover, although therapeutic efficacy was
not the focus of these trials, they nonetheless highlight that significant
improvements, such as a substantially increased editing efficiency,
greater expansion of tumor-reactive T cells, enhanced antigen speci-
ficity, and a clearer understanding of the specific T cell subtypes un-
dergoing the editing process, are required in order for an improved
patient response. Importantly, both trials support that CRISPR-
Cas9-based immunotherapy warrants further clinical investigation.ar Therapy: Methods & Clinical Development Vol. 21 June 2021 595
Table 2. Summary of all clinical trials utilizing CRISPR-Cas technologies to target the anti-tumor immune response
Trial status Date first posted
Identifier,




March 16, 2017 NCT03081715 1 China esophageal cancer PD-1 T cells
June 8, 2016 NCT02793856 1 China lung cancer PD-1 T cells
Recruiting




May 25, 2017 NCT03166878 1, 2 China leukemia/lymphoma TCR, B2M T cells
January 16, 2018 NCT03398967 1, 2 China leukemia/lymphoma
CD19 and CD20 or
CD22
T cells
June 4, 2018 NCT03545815 1 China solid tumors TCR, PD-1 T cells
July 29, 2019 NCT04035434 1 United States, Australia, Germany leukemia/lymphoma CD19 T cells
July 30, 2019 NCT04037566 1 China leukemia/lymphoma HPK1 T cells
January 28, 2020 NCT04244656 1
United States, Australia, Canada,
Spain
multiple myeloma BCMA T cells
June 5, 2020 NCT04417764 1 China liver cancer PD-1 T cells




June 18, 2020 NCT04438083 1 United States, Australia kidney cancer CD70 T cells
August 6, 2020 NCT04502446 1 United States, Australia lymphoma CD70 T cells
September 21,
2020
NCT04557436 1 United Kingdom leukemia CD19, CD52, TCR T cells
November 20,
2020
NCT04637763 1 United States lymphoma CD19 T cells
Not yet
recruiting
October 1, 2018 NCT03690011 1 United States leukemia/lymphoma CD7, CD28 T cells
Terminated January 16, 2018 NCT03399448 1 United States multiple myeloma TCR, PD-1 T cells
Withdrawn
August 11, 2016 NCT02863913 1 China bladder cancer PD-1 T cells
August 15, 2016 NCT02867332 1 China kidney cancer PD-1 T cells




NCT03747965 1 China solid tumors PD-1 T cells
Terms used in search: CRISPR, clustered regularly interspaced short palindromic repeat. PD-1, programmed cell death-1; EBV, Epstein-Barr virus; CISH, cytokine-induced SH2 pro-
tein; TCR, T cell receptor; HPK1, hematopoietic progenitor kinase 1; CD, cluster of differentiation; B2M, b2-microglobulin; BCMA, B cell maturation antigen. Search cutoff date:
March 1, 2020.
aUnknown studies denote those whose last known status was recruiting, not yet recruiting, or active, but had passed the completion date, and the status had not been last verified within
the past 2 years.
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ReviewMultiplex PD-1 and TCR knockout
Results from the first phase I clinical trial to test the safety of multiplex
CRISPR-Cas9 in treating patients with refractory cancer (Clinical-
Trials.gov: NCT03399448) were published in February 2020 by Stadt-
mauer et al.100 Three patients were recruited and CRISPR-Cas9 was
applied ex vivo to simultaneously disrupt expression of the PDCD1
gene (PD-1) and the endogenous T cell receptor a/b chain genes
(TRAC, TRBC), which encode the T cell surface receptor (TCR)
responsible for recognition of antigenic peptides presented in the
context of MHC class I and II molecules. Patient CD3+ T cells were
further transduced with TCRs specific for tumor antigen (NY-ESO-
1) recognition to enhance anti-tumor responses. The same ACT pro-
cess as above was used, with the engineered T cells being reinfused
back into each patient following editing and expansion. Stable disease
was seen in two patients, whereas the third patient exhibited disease596 Molecular Therapy: Methods & Clinical Development Vol. 21 June 2progression. Importantly, no serious (grade 3/4) adverse events were
caused by the treatment, with the re-infusion process and persistence
of transduced cells being well tolerated by all patients. Unlike the
plasmid-based delivery method used by Lu et al.,99 Stadtmauer
et al.100 utilized electroporation of ribonucleoprotein (RNP) com-
plexes composed of recombinant Cas9 loaded with equimolar mix-
tures of the three sgRNAs targeting each gene. In this case, the editing
efficiency was approximately 20% for PDCD1, 45% for TRAC, and
15% for TRBC. Although RNP delivery shows significant editing im-
provements compared to plasmid-based systems,99 incomplete edit-
ing of TRAC/TRBC genes has previously been reported to result in
mispairing and/or competing for expression between the transgenic
TCR and endogenous TCR.111 Additionally, iGUIDE,112 a variant
of GUIDE-seq (genome-wide unbiased identification of DSBs
enabled by sequencing),113 determined three significant off-targets.021
Figure 2. A combination CRISPR-Cas9 and dCas9-
and Cas13-based approach to improving anti-tumor
immunity
To date, immunotherapy approaches have aimed toward
improving effector cells, such as T cells. However, CRISPR
can also be used to counter immune evasion mechanisms
within the tumor cell itself. (i) dCas9 fused to activation
domains (Act) can be used to transcriptionally activate
markers of cell stress and neoplastic transformation (MICA,
MICB), thereby improving natural killer cell cytotoxicity
(perforin, granzymes) toward the target cell. (ii) Cas9 genetic
editing of host T cells ex vivo allows for re-engineering of the
T cell receptor (TCR) and removal of immune checkpoint
receptors (PD-1). Moreover, Cas13 gene inhibition can be
used in combination with this approach via knockdown of
corresponding immune checkpoint ligands (PD-L1) and
suppressive cytokine signaling (VEGF, TGF-b). Using either
of these approaches has been shown to improve the killing
capacity of immune effector cells. CRISPR-dCas9 linked to
Act can also be used to directly upregulate the genes
responsible for antigen presentation, MHC class I (iii) and
MHC class II (iv). Increased presentation of antigens im-
proves the likelihood of recognition and elimination via CD8+
T cells and CD4+ T cells, particularly those re-engineered
ex vivo to recognize specific tumor antigens.
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ReviewThe first, caused by the TRAC sgRNA, affected the transcriptional
unit of chloride intracellular channel 2 (CLIC2) and was deemed
acceptable, as it is not reported to be expressed in T cells. The remain-
ing two off-targets, within the genes encoding zinc finger protein 609
(ZFN609) and long intergenic non-protein coding RNA 377
(LINC00377), were attributed to the TRBC sgRNA. Both off-targets
were also deemed by the authors as acceptable due to their minimal
impact on the gene (ZFN609) and unknown role to date
(LINC00377). Despite the small sample size, Stadtmauer et al.100 sup-
ported that multiplexed CRISPR-Cas9-directed ACT is feasible and
appears to be safe for patients. Additionally, their trial reinforces
that off-targeting continues to be an important consideration in
any clinical application of CRISPR, and high-throughput sequencing
technologies should be used to enable their identification.114 Lastly,
although the high editing efficiency achieved in this trial using RNP
delivery verifies the established pre-clinical success of RNPs as the
preferred CRISPR delivery system,115,116 further improvements to
ex vivo CRISPR editing are clearly needed to see an improved patient
response. Namely, complete editing of TRAC/TRBC genes to elimi-
nate the possibility of TCR mispairing, a detailed understanding of
the specific T cell subsets undergoing editing, and extensive func-
tional elucidation of off-targets and their effects (particularly, novel
targets such as LINC00377) should be explored in future studies.
Using CRISPR-Cas9-based gene editing to target immune checkpoint
pathways, such as the PD-1/PD-L1 axis, in combination with re-engi-
neering the TCR for tumor specificity is expected to be an effective
strategy to improve immune recognition and, ultimately, to promote
the elimination of cancer cells. Moreover, use of these technologies
is likely to complement and enhance patient responsiveness and/orMoleculserve as an alternative to monoclonal antibody treatment that targets
immune checkpoint inhibitors (ICIs), such as PD-1 or CTLA-4, which
have been effective in only a subset of cancers.117–119 Aside from the
suitable safety documented in the above CRISPR-Cas9-based anti-tu-
mor immunotherapy clinical trials, the small sample sizes and high
variability in survival of individual patients limit definitive conclu-
sions on the efficacy of these treatments. However, with a number of
current CRISPR-based trials targeted toward boosting the immune
response via manipulation of immune-related genes (Table 2), more
conclusive results are likely to be seen during the coming months.
EPIGENETIC EDITING BY CRISPR-dCas9 CAN
IMPROVE ANTI-TUMOR HOST IMMUNITY
While major modalities of cancer immunotherapy, such as ICIs and
ACT, have revolutionized cancer treatment, not all patients respond
to these therapies.107,120 Often, durable immune responses occur in
patients with immunogenic (“hot”) tumors, characterized by infil-
trating CD4+ and CD8+ T cells and accumulation of pro-inflamma-
tory mediators.121 However, non-immunogenic (“cold”) tumors
that lack these components have significantly reduced response rates,
although some patients still respond, and cold tumors may require
conversion into a more hot-like phenotype in order to achieve a better
outcome.122 The CRISPR-dCas9-mediated epigenetic modulation of
tumor immunogenicity represents one such conversion method.
In this approach, dCas9-mediated transcriptional activation of
pro-immunogenic genes, or repression of genes involved in tumor
immunoevasion and immunosuppression, may enhance tumor
immunogenicity.122 Studies using these methods have shown success
in pre-clinical testing and hold great potential for novel immunother-
apeutics, as discussed below.ar Therapy: Methods & Clinical Development Vol. 21 June 2021 597
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ReviewPro-immunogenic transcriptional activation
In a seminal 2019 publication by Wang et al.,123 a multiplexed
dCas9-SAM system was harnessed to induce a genome-scale simul-
taneous upregulation of endogenous pro-immunogenic genes in tri-
ple-negative breast cancer (TNBC) E0771 cells, in order to improve
tumor immunogenicity. Given their role as inducers of T cell pro-
liferation and activation, a particular focus was directed toward
the upregulation of CD70, CD80, CD86, IFNa4, IFNb1, and IFNg
genes. CD70, present on antigen-presenting cells (APCs; dendritic
cells, B cells, and macrophages) and some T cells, is the cognate
ligand for the tumor necrosis factor (TNF) receptor family member
CD27 on T cells, and it provides an essential co-stimulatory signal
for T cell activation.124,125 Similarly present on APCs and some
T cells, CD80 and CD86 are cognate ligands for the co-stimulatory
receptor CD28 on T cells and also play a critical role in T cell acti-
vation.126,127 Type I (a and b) and type II (g) interferons (IFNs) are
potent cytokines that bind to the ubiquitously expressed IFNa
receptor (IFNaR) and IFNgR, respectively. Most cell types can pro-
duce IFNb, whereas IFNa is predominantly produced by plasmacy-
toid dendritic cells and IFNg is chiefly secreted by activated T cells
and natural killer (NK) cells. Together, type I and II IFN signaling
promotes innate and adaptive immunity in a variety of ways,
including activation of antigen presentation and chemokine pro-
duction, enhanced antibody generation, and stimulation of T cell
and NK cell cytotoxicity.128,129 The transcriptional upregulation
mediated by dCas9-SAM resulted in amplified presentation of a
model antigen (ovalbumin) in vitro. Moreover, the edited E0771
cells transplanted into syngeneic immunocompetent (C57BL/6J)
mice demonstrated significantly reduced tumor volume in vivo
compared to both immunodeficient (nude and Rag-deficient)
mice and CD4+ and CD8+ T cell-depleted immunocompetent
mice. Additionally, Wang et al.123 combined their activation system
with anti-CTLA4 monoclonal antibodies, which substantially
increased the efficacy of anti-CTLA4 therapy, with complete tumor
regression of established tumors. As expected, the increased tumor
immunogenicity via dCas9-mediated transcriptional activation of
pro-immunogenic genes increased CD4+ and CD8+ T cell infiltra-
tion into the tumor, thereby improving anti-tumor immunity.
The findings were also supported by Liu et al.’s130 earlier work
from 2017, where HeLa cells edited using the same dCas9-SAM sys-
tem to overexpress the IFNg gene exhibited enhanced apoptosis,
inhibited proliferation, and overall reduced tumor volume when im-
planted in immunodeficient (severe combined immunodeficiency
[SCID]) mice. Collectively, both works provide a proof of concept
that manipulating the transcriptome of tumors in favor of a pro-
immunogenic phenotype can greatly improve the anti-tumor im-
mune response and the response to ICIs. Moreover, the activation
of endogenous cytokines, such as IFNg, within the tumor is likely
to be an excellent starting point for this novel approach of
enhancing tumor immunogenicity.
Immunosuppressive pathway inhibition
The TGF-b signaling axis has been of interest owing to its dual role
in both tumor suppression and progression.131,132 When functioning598 Molecular Therapy: Methods & Clinical Development Vol. 21 June 2as an oncogenic activator, TGF-b signaling induces an immunosup-
pressive response,133 which is further potentiated by reciprocal pos-
itive regulatory interactions with Notch and Hippo signaling.134
Recently, microRNA-524 (miR-524) has been shown to silence the
TGF-b, Notch, and Hippo pro-tumorigenic signaling pathways
simultaneously by suppression of SMAD2, HES1, and TEAD1 genes,
respectively, making it an attractive target for cancer immuno-
therapy.135 As such, in 2019, Liu et al.136 aimed to explore the poten-
tial of dCas9-VP64-mediated miRNA-524 transcriptional activation
as a cancer immunotherapy strategy to inhibit TGF-b/Notch/Hippo
signaling in vivo. To this end, a pH-responsive multistage delivery
nanoparticle (MDNP) was developed to deliver pDNA encoding
the CRISPR-dCas9 system and sgRNA biomolecular components
targeting the miR-524 locus. The systemic injection of MDNP/
dCas9-miR-524 into tumor-bearing immunodeficient (nude) mice
with TNBC MDA-MD-231 xenograft evidenced reduced SMAD2,
HES1, and TEAD1 gene and protein expression, significantly inhib-
iting tumor growth and higher levels of tumor apoptosis. Although
the direct impact of miR-524 activation on tumor immunogenicity
was not explored in this study, inhibition of the TGF-b axis is
well recognized to improve immune cell infiltration as a conse-
quence of the reduction in immunosuppression, tumor migration,
and angiogenesis.137,138 Altogether, Liu et al.’s136 work provides a
strong rationale for further exploration of miR-524 in cancer immu-
notherapy and highlights the potential of CRISPR-dCas9 technolo-
gies to inhibit immunosuppressive pathways for an improved anti-
tumor response.
Although not applied in pre-clinical studies, a number of early works
also suggest that dCas9-based methods can help circumvent other
major tumor immunoevasion mechanisms. For instance, impairment
of Treg immunosuppressive function by dCas9-KRAB-mediated
forkhead box P3 (FoxP3) transcriptional repression,139,140 dCas9-
SAM-mediated enhancement of neoplastic transformation markers,
such as MICA,141,142 and dCas9-KRAB-directed repression of immu-
nosuppressive cytokine receptors143 have demonstrated that dCas9-
mediated epigenetic engineering has potential in multiple facets of
cancer immunotherapy. Ultimately, dCas9-mediated epigenetic edit-
ing to improve tumor immunogenicity and/or boost the host’s anti-
tumor immune response opens new therapeutic avenues, particularly
in combination with ICI or ACT therapies (Figure 2).
THE CRISPR-CAS13 SYSTEM IS A NOVEL GENE
INTERFERENCE TOOL IN CANCER IMMUNOTHERAPY
Significant attention has been directed toward applying CRISPR-
Cas13 (RNA-targeting) technology as a diagnostic in the detection
of low-frequency cancer somatic mutations144 and in RNA edit-
ing.85,145 Additionally, the CRISPR-Cas13 system has demonstrated
highly efficient and specific knockdown of oncogenic mutant
drivers,146 gene fusions,88 and ncRNA147 transcripts in vitro with
minimal off-targets, highlighting its potential for use as an RNA-
based therapeutic tool. More recently, the potential of Cas13-based
gene suppression in cancer immunotherapy has drawn attention
due to its growing success in pre-clinical studies, as explored below.021
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As discussed above, CRISPR-mediated PD-1 knockout T cells have
shown acceptable toxicity profiles, yet their efficacy remains limited.
Moreover, although PD-1 knockout therapies largely focus on T cells,
other important immune effectors, such as NK cells, are also inhibited
by the PD-1/PD-L1 axis.148 Therefore, as opposed to targeting PD-1
expression on specific cell types, Zhang et al.149 explored the capa-
bility of CRISPR-Cas13a to silence PD-L1 expression at the tumor
cell surface to improve overall anti-tumor immunity. To this end,
pDNA encoding Cas13a and crRNAs targeting PD-L1 transcripts
were systemically delivered in vivo using a pH and hydrogen peroxide
(H2O2)-responsive dual-locking nanoparticle (DLNP). Following in-
jection of DLNP/Cas13-crRNA into melanoma B16F10-bearing
immunocompetent mice, significant tumor growth suppression and
improved survival was observed. Furthermore, a significant reduction
in TGF-b and elevation in IFNg, TNF-a (predominantly secreted by
macrophages and promotes T cell activation), IL-2 (secreted by acti-
vated T cells and promotes T cell proliferation), and IL-12 (secreted
by activated APCs to activate NK cells and induce T cell differentia-
tion) levels were seen in treated tumors, suggesting activation of anti-
tumor immunity. Knockdown of PD-L1 by Cas13 also increased the
number of CD8+ tumor-infiltrating T cells, reduced the number of
myeloid-derived suppressor cells (MDSCs), and induced a tumor-
associated macrophage polarization from a tumor-promoting M2-
like (CD206hiCD11b+F4/80+) to a more anti-tumor M1-like
(CD80hiCD11b+F4/80+) phenotype in the tumor microenvironment.
This work suggests that Cas13a can successfully suppress tumor PD-
L1 expression and aid in eliciting an effective anti-tumor immune
response (Figure 2).
VEGF pathway disruption
TheVEGF/VEGF receptor pathway constitutes one of themost prom-
ising therapeutic targets due to its significant immunosuppressive role
in the tumor and surrounding microenvironment. Previously,
obstruction of VEGF receptor 2 (VEGFR2)150 and its downstream
signaling pathways, BCL-2 and Survivin,151 via small-molecule inhib-
itors or neutralizing antibodies has shown success in blocking tumor
growth and prolonging survival. However, limitations, such as tempo-
rary efficacy, treatment resistance, and adverse complications, have
justifiably limited their clinical use. With this in mind, Fan et al.152
explored the capacity of the Cas13a system to target VEGFR2, BCL-
2, and Survivin transcripts simultaneously in tumor cells. Plasmid
DNA containing Cas13a and crRNA tandem sequences designed to
target VEGFR2/BCL-2/Survivin transcripts were encapsulated in a
dual-component liposome system coated in VEGFR2monoclonal an-
tibodies. The Cas13a/liposome was then perfused via intravesical
administration into bladder cancer 5637 cell-bearing immunodefi-
cient (nude) mice, resulting in significantly reduced transcription
levels of VEGFR2/BCL-2/Survivin and inhibited tumor growth. It is
well established that inhibition of the VEGF/VEGFR axis reduces
angiogenesis and Treg/MDSC accumulation, thereby promoting im-
mune cell infiltration into the tumor.153–155 These findings therefore
support that Cas13a represents an emerging precision medicine plat-
form for the inhibition of tumor growth by targeting pro-oncogenicMoleculsignaling pathways, such as VEGF/VEGFR, in a highly selective
manner.
More recent studies have shown that dCas13-fusion (RNA editing)
proteins can also achieve efficient knockdown of endogenous RNA
transcripts by catalyzing the demethylation of m6A (N6-methylade-
nosine),156 or by the degradation of m6A-marked RNA,157 resulting
in gene suppression. These early works suggest that dCas13-based
technologies targeted toward m6A modifications may offer an alter-
native to Cas13-mediated alteration of post-transcriptional RNA
fate. Although more investigation is required to explore the efficacy
and safety of Cas13 in cancer immunotherapy, studies support that
Cas13 has the potential to function as a therapeutic through its tar-
geted manipulation of tumor immunogenicity (Figure 2).
CONSIDERATIONS FOR CRISPR-BASED CANCER
IMMUNOTHERAPY
To date, many reviews have discussed the key considerations sur-
rounding use of CRISPR in treating human diseases. For further de-
tails on the concerns surrounding use of CRISPR-based therapeutics
in a general sense, we refer to excellent previously published re-
views.74,158–161 In this section, however, we focus specifically on the
concerns associated with CRISPR use in cancer immunotherapy.
Pre-existing CRISPR immunity
Given that CRISPR systems are derived from common human path-
ogens, such as Streptococcus pyogenes and Staphylococcus aureus, the
presence of pre-existing immunity from prior exposure remains a
major concern in the safety and efficacy of these technologies. Princi-
pally, in the context of cancer immunotherapy where potent immune
activation is the goal, the extent of anti-Cas antibodies and/or T cells
that may interfere with CRISPR-based treatment needs to be eluci-
dated.119,162 Recently, three studies have shown that both antibodies
and T cells against Streptococcus pyogenes Cas9 (SpCas9) and Staph-
ylococcus aureus Cas9 (SaCas9) are indeed present in many individ-
uals, supporting that further investigation is required. First, Simhadri
et al.163 highlighted that approximately 2.5% and 10% of donors (a
predominantly white cohort from the United States) tested positive
for anti-SpCas9 and anti-SaCas9 antibodies in human sera, respec-
tively, by enzyme-linked immunosorbent assay (ELISA). Second,
Wagner et al.164 showed using flow cytometry that approximately
96% of donors (ethnicity unknown) had SpCas9-reactive peripheral
CD4+ and CD8+ T cells as measured by CD137 expression. Lastly,
Charlesworth et al.165 identified using PBMCs that approximately
58% and 78% of donors (a predominantly white cohort from the
United States) had antibodies against SpCas9 and SaCas9 detected us-
ing ELISA, respectively. Moreover, approximately 67% and 78% of
donors were positive for SpCas9- and SaCas9-reactive CD4+/CD8+
T cells, respectively, as confirmed by IFNg enzyme-linked immuno-
spot (ELISpot), intracellular cytokine staining (ICS), and/or surface
expression of CD137 or CD154. Although these studies complement
one another in highlighting the prevalence of pre-existing immunity
to Cas9, further research is still required to elucidate whether the pres-
ence of anti-Cas antibodies or anti-Cas T cells are at biologicallyar Therapy: Methods & Clinical Development Vol. 21 June 2021 599
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therapy.
Ultimately, if in healthy hosts the potential exists for an anti-CRISPR
immune response to impede the efficacy of CRISPR-based therapeu-
tics, this is likely to be further exacerbated in patients undergoing
CRISPR/ICI or CRISPR/ACT combination cancer immunotherapy
where effector immune cells are in an activated state. In order to
circumvent this issue for Cas9 genetic editing, it has been proposed
that transient Cas9 expression ex vivo outside of direct immune con-
tact and reinfusion into the host once the Cas9 protein has been
cleared may be a solution.165 This may help to explain why
CRISPR-based clinical trials to date—all using ex vivo editing—
have not shown adverse Cas9-reactive T cell responses. However,
the likelihood of producing anti-Cas9 memory T cells during the
ex vivo editing process is still unknown, and moreover this ex vivo
method cannot be applied to dCas9 or Cas13 systems where in vivo
use is vital. In these cases, preclinical assessment of Cas immunoge-
nicity or specific delivery methods that do not allow for CRISPR-im-
mune interactions until cargo release may be required. Examples of
successful delivery systems designed with this is mind include the
MDNP136 and DLNP149 methods discussed in the pre-clinical
dCas9 and Cas13 sections, respectively. These delivery systems are
also necessary to ensure that the CRISPR cargo is delivered directly
to the target tissue. For instance, the release of CRISPR-dCas9 with
sgRNAs targeting pro-immunogenic genes in unintended tissues
may elicit an adverse pro-inflammatory and/or autoimmune
response. Ultimately, averting an anti-CRISPR immune response
will likely require a joint approach of checking for pre-existing immu-
nity and selecting for tissue-specific, multi-layered, non-immuno-
genic delivery systems.
Retroactivity in multiplex CRISPR applications
One of the key benefits of CRISPR-based systems is their capability to
multiplex crRNAs and, thus, to regulate multiple targets simulta-
neously. For cancer immunotherapy, it is highly likely that clinical
benefit will only be achieved throughmultiplexing, as multiple genetic
elements require editing. However, as the number of target sites in-
creases, there is also a subsequent increase in the competition between
crRNAs to guide the Cas protein to their target site. Competition be-
tween crRNAs, termed retroactivity,166 results in a decrease in the
performance of CRISPR-Cas and severely hinders the ability to pre-
dict crRNA targeting efficiency. This presents a major obstacle in can-
cer immunotherapy, as it is essential that maximum gene editing and
transcriptional regulation is achieved. In other contexts, retroactivity
has been mitigated by using conditional crRNAs, whose activity is
dependent on the presence or absence of an RNA trigger.167 However,
this is unlikely to serve in cancer immunotherapy, as simultaneous
targeting is required. An alternative method more applicable to over-
coming retroactivity in cancer immunotherapy lies in the exploitation
of target hierarchy. In this approach, targets of high priority are allo-
cated multiple crRNAs, while lower priority targets are allocated only
a single crRNA.66 This method may ensure that all sites are targeted,
but those of high importance are emphasized. Furthermore, it is still600 Molecular Therapy: Methods & Clinical Development Vol. 21 June 2unclear as to howmany crRNAs can be expressed in vivo for an effec-
tive multiplexing strategy, while maintaining editing efficacy at all
target sites. This knowledge is fundamental to achieving the desired
effectiveness of CRISPR-based therapies. In the case of cancer immu-
notherapy, it is expected that not all target sites will have the same
impact on tumor immunogenicity or immune effector cytotoxicity.
Also, inherent genetic and/or epigenetic differences between patients
at specific target sites is highly likely. Therefore, effective multiplexed
strategies that target these different loci is essential.
Altogether, if pre-existing CRISPR immunity and retroactivity can be
mitigated via improved delivery systems and crRNA prioritization/
customization to particular patients, then CRISPR-based cancer
immunotherapy may yet develop to become an effective clinical
treatment.
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
The ability of CRISPR-based technologies to efficiently modify
specific loci at the genetic and epigenetic level provides novel oppor-
tunities to reprogram the immune response for improved tumor
elimination. To date, CRISPR-Cas9 genetic editing has successfully
improved the killing capacity of T cells via the elimination and/or
modification of key cell surface molecules, such as PD-1 and the
TCR. However, although shown to be safe when used ex vivo,
Cas9’s potential to bind to non-target DNA sequences (off-targets),
thereby causing permanent genomic instability or disruption of
otherwise normal host genes, has consistently remained a major
concern.168,169 Alternatively, the development of dCas9- and
Cas13-based systems that work transiently, are reversible, and elimi-
nate the risk of long-lasting consequences are expected to be safer,
and therefore more clinically relevant, for in vivo use. Technologies
such as dCas9 in particular show significant advantages, as it mediates
straightforward upregulation or downregulation of transcription and
editing of epigenetic marks within the same platform, which signifi-
cantly expand its applications in cancer therapeutics. Moreover, these
systems are increasingly being developed as inducible structures al-
lowing for precise control of epigenetic editing at will.170 Still, safe
and precise delivery mechanisms are yet to be addressed in a compre-
hensive way, and the potential for adverse immune reactions chal-
lenge clinical CRISPR applications. Altogether, based on safety and
versatility, epigenetic editing platforms such as dCas9 and Cas13
are likely to overtake Cas9 genetic editing platforms in clinical
applications.
Future applications of CRISPR-based technologies in the immuno-
therapy field are likely to expand heavily on epigenetic editing by
dCas9 or Cas13. Epigenetically reprogramming immune evasion
mechanisms, such as rescuing MHC class I/II expression, halting
MICA/B shedding, and repressing the activation of suppressive cyto-
kines, is an attractive therapeutic avenue, as doing so has the potential
to greatly improve host immunity. Furthermore, the expanding
knowledge of the role of distinct immune checkpoint inhibitors will
offer grounds for the identification of additional checkpointmolecules021
www.moleculartherapy.org
Reviewto be edited in multiplexed CRISPR applications. Selective epigenetic
targeting of immune checkpoints in effector immune cells or at the tu-
mor cell surface to improve in vivo immune activation and efficacy is
likely to improve patient outcomes in the clinic. Other potential appli-
cations may involve the epigenetic manipulation of cells used in ACT
aiming at enhancing intra-tumoral recruitment and persistence of
these cells through the upregulation of relevant chemokine receptors,
such as CXCR2 and CXCR3, which greatly improve T cell localization
and migration to tumors.171–173 In principle, this strategy could be
combined with epigenetic upregulation of the genes encoding for
the corresponding chemokine ligands on tumor cells, thus facilitating
the treatment of cold-like tumors, which are poorly amenable by cur-
rent immunotherapies. Similarly, recent studies have highlighted the
complexity in the development of exhausted T cells and NK cells (fail-
ure to produce cytokines, lack of proliferation, and high expression of
inhibitory receptors),174–177 with significant epigenetic changes iden-
tified in chronically stimulated NK cells178 and T cells that failed to
respond to anti-PD-1 therapy.179,180 Reinvigoration of exhausted
and dysfunctional cell subsets using targeted epigenetic CRISPR edit-
ing of key genes, such as TCF1 (transcription factor encoded by TCF7
crucial for T cell persistence and NK cell survival),181–183 may assist in
improving patient responses to ICI therapies and overall anti-tumor
immunity. Importantly, the extent to which CRISPR-based technolo-
gies can alter the tumor landscape is still unknown; however, through
multiplexed approaches, it is hopeful that durable immune responses
can be achieved. Alhough in its infancy, precise epigenetic editing by
dCas9 and Cas13 is likely to become a powerful tool in both basic sci-
entific research and clinical application, especially when combined
with Cas9-mediated genetic editing.
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